Loading...
Loading...
NEW YORK, NY · CIK 0001263508
Portfolio Value
$11.40B
Positions
128
New
10
Increased
26
Decreased
18
Sold Out
16
BAKER BROS. ADVISORS LP (NEW YORK, NY) reported a portfolio value of $11.40B across 128 positions in their Q2 2015 SEC 13F filing (period ending 2015-06-30). The top 10 positions account for 75.1% of the portfolio.
Top 30 holdings by portfolio weight. Block width = holding percentage. Green = new/increased, red = reduced, gray = unchanged.
| # | Stock | Value↓ | Weight | Change |
|---|---|---|---|---|
| 1 | INCYIncyte Corporation | $1.55B | 13.59% | +0.1% |
| 2 | SGENEURSeattle Genetics, Inc. | $1.49B | 13.11% | +6.9% |
| 3 | ALXNAlexion Pharmaceuticals, Inc. | $1.18B | 10.37% | New |
| 4 | ABBVAbbVie Inc. | $965.76M | 8.47% | New |
| 5 | ACADACADIA Pharmaceuticals Inc. | $857.76M | 7.52% | - |
| 6 | Incyte Corporation Notes 1.25% 11/15/2020 144A | $567.76M | 4.98% | - |
| 7 | BMRNBioMarin Pharmaceutical Inc. | $560.15M | 4.91% | -2.5% |
| 8 | Incyte Corporation Notes 0.375% 11/15/2018 144A | $529.52M | 4.64% | - |
| 9 | INCY 4.75 10/01/15Incyte Corporation Notes 4.75% 10/1/2015 144A | $478.83M | 4.20% | - |
| 10 | GHDXGenomic Health Inc. | $379.55M | 3.33% | +0.0% |
| Stock | Value | Shares |
|---|---|---|
| ALXNAlexion Pharmaceuticals, Inc. | $1.18B | 6,542,599 |
| ABBVAbbVie Inc. | $965.76M | 14,373,538 |
| LIFEUSDaTyr Pharma Inc. | $43.25M | 2,335,125 |
| LKFTGalapagos NV | $19.02M | 369,276 |
| MCRB1EURSeres Therapeutics, Inc. | $5.19M | 125,000 |
| CRISCuris, Inc. | $3.57M | 1,077,663 |
| Immune Design Corp. | $3.08M | 148,937 |
| ADAPYAdaptimmune Therapeutics plc | $1.83M | 100,000 |
| Ritter Pharmaceuticals, Inc. | $1.78M | 400,000 |
| TENXTenax Therapeutics Inc. | $1.31M | 355,348 |
Get alerts when BAKER BROS. ADVISORS LP files new 13F holdings.